740 related articles for article (PubMed ID: 17519387)
1. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
Vanover KE; Weiner DM; Makhay M; Veinbergs I; Gardell LR; Lameh J; Del Tredici AL; Piu F; Schiffer HH; Ott TR; Burstein ES; Uldam AK; Thygesen MB; Schlienger N; Andersson CM; Son TY; Harvey SC; Powell SB; Geyer MA; Tolf BR; Brann MR; Davis RE
J Pharmacol Exp Ther; 2006 May; 317(2):910-8. PubMed ID: 16469866
[TBL] [Abstract][Full Text] [Related]
3. Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT 2A/2C receptors.
Su YA; Si TM; Zhou DF; Guo CM; Wang XD; Yang Y; Shu L; Liang JH
Eur J Pharmacol; 2007 Jun; 564(1-3):123-30. PubMed ID: 17395179
[TBL] [Abstract][Full Text] [Related]
4. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
[TBL] [Abstract][Full Text] [Related]
5. ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
Li Z; Ichikawa J; Huang M; Prus AJ; Dai J; Meltzer HY
Psychopharmacology (Berl); 2005 Dec; 183(2):144-53. PubMed ID: 16220333
[TBL] [Abstract][Full Text] [Related]
6. Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist.
Snigdha S; Horiguchi M; Huang M; Li Z; Shahid M; Neill JC; Meltzer HY
J Pharmacol Exp Ther; 2010 Feb; 332(2):622-31. PubMed ID: 19864614
[TBL] [Abstract][Full Text] [Related]
7. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
[TBL] [Abstract][Full Text] [Related]
8. The role of serotonin receptors in the action of atypical antipsychotic drugs.
Meltzer HY; Massey BW
Curr Opin Pharmacol; 2011 Feb; 11(1):59-67. PubMed ID: 21420906
[TBL] [Abstract][Full Text] [Related]
9. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
[TBL] [Abstract][Full Text] [Related]
10. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol.
Millan MJ; Schreiber R; Dekeyne A; Rivet JM; Bervoets K; Mavridis M; Sebban C; Maurel-Remy S; Newman-Tancredi A; Spedding M; Muller O; Lavielle G; Brocco M
J Pharmacol Exp Ther; 1998 Sep; 286(3):1356-73. PubMed ID: 9732399
[TBL] [Abstract][Full Text] [Related]
11. Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats.
Wadenberg MG; Browning JL; Young KA; Hicks PB
Pharmacol Biochem Behav; 2001 Mar; 68(3):363-70. PubMed ID: 11325387
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
[TBL] [Abstract][Full Text] [Related]
13. Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats.
Creed-Carson M; Oraha A; Nobrega JN
Behav Brain Res; 2011 Jun; 219(2):273-9. PubMed ID: 21262266
[TBL] [Abstract][Full Text] [Related]
14. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
Meltzer HY; Elkis H; Vanover K; Weiner DM; van Kammen DP; Peters P; Hacksell U
Schizophr Res; 2012 Nov; 141(2-3):144-52. PubMed ID: 22954754
[TBL] [Abstract][Full Text] [Related]
15. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
Marquis KL; Sabb AL; Logue SF; Brennan JA; Piesla MJ; Comery TA; Grauer SM; Ashby CR; Nguyen HQ; Dawson LA; Barrett JE; Stack G; Meltzer HY; Harrison BL; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2007 Jan; 320(1):486-96. PubMed ID: 17038512
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
Langlois X; Megens A; Lavreysen H; Atack J; Cik M; te Riele P; Peeters L; Wouters R; Vermeire J; Hendrickx H; Macdonald G; De Bruyn M
J Pharmacol Exp Ther; 2012 Jul; 342(1):91-105. PubMed ID: 22490380
[TBL] [Abstract][Full Text] [Related]
17. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release.
Ichikawa J; Ishii H; Bonaccorso S; Fowler WL; O'Laughlin IA; Meltzer HY
J Neurochem; 2001 Mar; 76(5):1521-31. PubMed ID: 11238736
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of the role of 5-HT(2) receptor antagonism during subchronic antipsychotic drug administration in rats.
Kruzich PJ; See RE
Brain Res; 2000 Sep; 875(1-2):35-43. PubMed ID: 10967296
[TBL] [Abstract][Full Text] [Related]
19. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.
Vanover KE; Betz AJ; Weber SM; Bibbiani F; Kielaite A; Weiner DM; Davis RE; Chase TN; Salamone JD
Pharmacol Biochem Behav; 2008 Oct; 90(4):540-4. PubMed ID: 18534670
[TBL] [Abstract][Full Text] [Related]
20. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Schizophr Res; 2008 Oct; 105(1-3):224-35. PubMed ID: 18710798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
